remaining questions on the use of frontline cdk4/6 inhibitors endocrine therapy
Published 1 year ago • 178 plays • Length 1:12Download video MP4
Download video MP3
Similar videos
-
2:07
remaining questions regarding the use of frontline cdk4/6 inhibitors and endocrine therapy
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
0:50
investigating mechanisms of resistance to cdk4/6 inhibitors
-
1:00
dr. tolaney on remaining questions with cdk4/6 inhibitors in hr /her2- breast cancer
-
1:08
overcoming resistance to cdk4/6 inhibitors in er breast cancer via ctdna
-
0:53
postmonarche: abemaciclib fulvestrant in hr /her2- mbc following cdk4/6i & endocrine therapy
-
2:31
pf-07220060 in hr her2- mbc who progressed on prior cdk4/6 inhibitors and endocrine therapy
-
5:07
what is the role of cdk4/6 inhibitors in early breast cancer?
-
6:15
breast cancer at esmo 2020: cdk4/6 inhibitors and checkpoint inhibitors
-
1:04
biomarkers to help predict response to cdk4/6 inhibitors
-
2:07
dr ma on questions regarding treatment sequencing in cdk4/6 inhibitor–resistant breast cancer
-
4:17
cdk4/6 inhibitors & endocrine therapy in breast cancer
-
4:54
monarch 3 study: cdk4/6 inhibitors in the treatment of metastatic breast cancer
-
4:35
cdk4/6 inhibitors & endocrine therapy: adverse events
-
2:22
cdk4/6 inhibitors in early stage hr /her2- disease
-
1:26
ribecca: ribociclib, a cdk4/6 inhibitor in er breast cancer
-
0:56
remaining questions on the management of her2-low breast cancer